Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1HER2-expressing Advanced Solid Tumors 1HER2 Positive Metastatic Breast Cancer 1HER-2 Positive Colorectal Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Metastatic 1Brain Neoplasms 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × pyrotinib × Clear all
NCT04582968 2023-01-18

Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

Fudan University

Phase 1/2 Unknown
39 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡